Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.68B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $7.35K in total
- 1
- 13F holdersQ2 2026, +40 vs. previous quarter
- 104
- 13F valueReported value at the end of Q2 2026
- $1.68B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding DMRA, Q2 2026
1 superinvestor reports holding Damora Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.2%
Damora Therapeutics, Inc.'s share of the portfolio
- Shares
- 2,311,082
- Value
- $60.1M
Latest insider trades
Open-market purchases and sales by Damora Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 7, 2026 (view filing)8:00 PM ET | Jul 6 | 1 day | Winslow GarrettGeneral Counsel | SSale | −245 | $29.98 | −$7.35K | −9.7%2.29K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Schambye Hans T.Chief Executive Officer | SSale | −700 | $21.38 | −$15.0K | −13.0%4.68K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Winslow GarrettGeneral Counsel | SSale | −255 | $21.38 | −$5.45K | −12.1%1.85K after | |
| Jan 6, 2026 (view filing) | Jan 2 | 4 days | Firmani LoriChief Financial Officer | SSale | −135 | $21.41 | −$2.89K | −12.7%931 after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Schambye Hans T.Chief Executive Officer | SSale | −735 | $3.38 | −$2.48K | −15.5%4.02K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Winslow GarrettGeneral Counsel | SSale | −260 | $3.39 | −$881.4 | −15.4%1.43K after | |
| Jul 8, 2025 (view filing) | Jul 3 | 5 days | Firmani LoriInterim CFO | SSale | −147 | $3.39 | −$498.33 | −17.5%692 after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Winslow GarrettGeneral Counsel | SSale | −471 | $5.60 | −$2.64K | −31.8%1.01K after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Firmani LoriInterim CFO | SSale | −261 | $5.63 | −$1.47K | −36.0%465 after | |
| Jan 7, 2025 (view filing) | Jan 3 | 4 days | Schambye Hans T.Chief Executive Officer | SSale | −1.34K | $5.60 | −$7.51K | −28.3%3.40K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Damora Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,232,979 | $240.1M | 0.01% | +187,498+2.1% | Added |
| Fairmount Funds Management LLC | 8,713,000 | $226.6M | 14.98% | 00.0% | Unchanged |
| Avoro Capital Advisors LLC | 3,783,000 | $98.4M | 0.88% | 00.0% | Unchanged |
| VR Adviser, LLC | 3,603,595 | $93.7M | 2.84% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,162,068 | $82.2M | 0.00% | +2,939,631+1,321.6% | Added |
| FCPM III Services B.V. | 2,441,000 | $63.5M | 8.46% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 2,399,702 | $62.4M | 0.54% | +3920.0% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 2,311,082 | $60.1M | 0.17% | 00.0% | Unchanged |
| Jupiter Topco LLC | 2,282,804 | $59.3M | 0.02% | +2,282,804 | New |
| Remedium Capital Partners, LLC | 2,045,473 | $53.2M | 11.78% | 00.0% | Unchanged |